Display Settings:

Format

Send to:

Choose Destination
    Forsch Komplementmed. 2010 Apr;17(2):95-102. Epub 2010 Apr 20.

    Acupuncture in seasonal allergic rhinitis (ACUSAR)--design and protocol of a randomised controlled multi-centre trial.

    Source

    Institute for Social Medicine, Epidemiology, and Health Economics, Charité - University Medical Center, Berlin, Germany. benno.brinkhaus@charite.de

    Abstract

    BACKGROUND:

    We report on the study design and protocol of a randomised controlled trial (Acupuncture in Seasonal Allergic Rhinitis, ACUSAR) that investigates the efficacy of acupuncture in the treatment of seasonal allergic rhinitis (SAR).

    OBJECTIVE:

    To investigate whether acupuncture is non-inferior or superior to (a) penetrating sham acupuncture and (b) rescue medication in the treatment of SAR.

    DESIGN:

    3-armed, randomised controlled multi-centre trial with a total follow-up time of 16 weeks in the 1st year and 8 weeks in the 2nd year.

    SETTING:

    41 physicians in 37 out-patient units in Germany specialised in acupuncture treatment.

    PATIENTS:

    400 seasonal allergic rhinitis patients with clinical symptoms and test-positive (skin-prick test and/or specific IgE) to both birch and grass pollen.

    INTERVENTIONS:

    Patients will be randomised in a 2:1:1 ratio to one of three groups: (a) semi-standardised acupuncture plus rescue medication (cetirizine); (b) penetrating sham acupuncture at non-acupuncture points plus rescue medication; or (c) rescue medication alone for 8 weeks (standard treatment group). Acupuncture and sham acupuncture will consist of 12 treatments per patient over 8 weeks.

    MAIN OUTCOME MEASURES:

    Average means of the Rhinitis Quality of Life Questionnaire (RQLQ) overall score and the Rescue Medication Score (RMS) between weeks 6 and 8 in the first year, adjusted for baseline values.

    OUTLOOK:

    The results of this trial available in 2011 will have a major impact on the decision of whether acupuncture should be considered as a therapeutic option in the treatment of SAR.

    Copyright 2010 S. Karger AG, Basel.

    PMID:
    20484917
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Icon for S. Karger AG, Basel, Switzerland

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk